Founded in 1906 in Vicenza, Italy, Zambon has evolved from a family‑owned chemical‑pharmaceutical enterprise into a modern multinational group headquartered in Bresso, Milan . Operating across Europe, South America and Asia, Zambon employs around 2,400–2,600 people and generated approximately €830 million in revenue in 2024. The company focuses on treatments for severe respiratory diseases, central nervous system disorders (notably Parkinson’s), cough and cold, women’s health and pain management, driving innovation through its research ventures, integrated production facilities, and its OpenZone scientific campus.

Key Products & Services

• Prescription pharmaceuticals for severe respiratory conditions such as chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans syndrome (BOS), non‑cystic fibrosis bronchiectasis (NCFB), and related therapies

• Neurological and CNS therapies, with ongoing research in Parkinson’s disease and related disorders.

• Women’s healthcare and pain management products, including over‑the‑counter and prescription medications.

• Fine chemicals and APIs, developed through Zach System, offering advanced intermediates for pharmaceutical manufacture.

• Research venture capabilities, via Z‑Cube, developing modern healthcare solutions that integrate digital technologies with traditional therapies.

• Scientific campus and innovation infrastructure, including OpenZone, the Health & Quality Factory, and Benvivere workspaces, which promote scientific collaboration and professional growth.

With over a century of heritage rooted in Italian innovation, Zambon now leverages its global footprint to deliver high‑quality pharmaceutical and chemical solutions. Driven by core values of integrity, modesty and patient‑centric care, the company continues to pioneer therapies for complex diseases while supporting scientific progress through research ventures and collaborative infrastructure.